The Federal Trade Commission (FTC) and four states have sued the World Professional Association for Transgender Health (WPATH) over its guidelines for pediatric gender treatments. The lawsuit alleges that WPATH made deceptive claims about the treatments and that its members profited from them.

Allegations Against WPATH

The FTC claims that WPATH failed to disclose the side effects of certain pediatric medical transition services, including hormone treatments. The agency also alleges that doctors repeated false or misleading statements about the safety and efficacy of these treatments, which were found in WPATH guidelines.

FTC Chairman Andrew Ferguson stated, ‘Parents have a right to make informed decisions about their children’s health. The FTC will not allow parents and children to be deceived by medical organizations and providers who are prioritizing profit over children’s health and safety.’

Response from WPATH

WPATH has responded to the lawsuit, stating that its guidelines call for care that is tailored to individual patients, rather than a ‘one size fits all’ approach. The organization claims that its standards are designed to promote the highest level of care for transgender and gender-diverse patients through open dialogue and clear communication.

Lawrence Gostin, an international public health expert at Georgetown University, has expressed concerns about the lawsuit, stating that it represents a ‘significant expansion’ of the FTC’s past approach to healthcare enforcement. Gostin believes that the agency is using consumer protection law to challenge a medical association’s standards of care, which is unusual.

The lawsuit has also been criticized for its potential impact on the rights of parents to make decisions about their children’s healthcare. The case is likely to be closely watched by those interested in parental rights and the regulation of pediatric gender treatments.

Original reporting: Texarkana Gazette — read the source article.